Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$53.76 USD

53.76
22,196,871

+0.86 (1.63%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Exelixis's Cabometyx Positive for First-Line Kidney Cancer

Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

    Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada

    Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.

      Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205

      Bristol-Myers Squibb Company (BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.

        J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use

        Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.

          Arpita Dutt headshot

          Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused

          Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.

            Exelixis Initiates Cabozantinib-Tecentriq Combination Trial

            Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.

              Novartis, Bristol-Myers Collaborate for Opdivo Combination

              Novartis AG (NVS) and Bristol-Myers Squibb Company (BMY) collaborate for Opdivo combination therapies.

                Incyte Provides Updated Data on Cancer Combination Therapies

                Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma.

                  Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo

                  Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.

                    Amgen (AMGN) Presents Positive Clinical Data on Cancer Drugs

                    Amgen, Inc. (AMGN) presented encouraging results from a phase III study, evaluating its marketed drug Xgeva (denosumab) for an expanded indication at the American Society of Clinical Oncology.

                      Incyte Announces Data on Enzyme Inhibitor with Keytruda

                      Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.

                        Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU

                        Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).

                          Arpita Dutt headshot

                          Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More

                          Lilly (LLY) posted positive data on Cyramza while Teva's migraine drug delivered positive results in a late-stage study.

                            Why Is Bristol-Myers (BMY) Down 3.1% Since the Last Earnings Report?

                            Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                              Bristol-Myers Partners Array to Investigate Cancer Candidate

                              Bristol-Myers Squibb Company (BMY) and Array BioPharma (ARRY) entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's binimetinib in combination with the former's Opdivo and Opdivo + Yervoy regimen.

                                Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer

                                Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.

                                  Celldex's Immuno-Oncology Pipeline Continues to Impress

                                  On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data

                                    Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.

                                      Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer

                                      Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).

                                        Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase

                                        Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.

                                          Arpita Dutt headshot

                                          Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More

                                          This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.

                                            Sheraz Mian headshot

                                            New Research Reports for Britol-Myers, Pricline & Phillips 66

                                            Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers (BMY), Priceline (PCLN) and Phillips 66 (PSX).

                                              Incyte (INCY) Announces Positive Data on Enzyme Inhibitor

                                              Incyte Corporation (INCY) recently announced that new data was published from the ongoing trial, ECHO-202 online by the American Society of Clinical Oncology (ASCO).

                                                Biogen (BIIB) Buys Stroke Candidate Cirara for $120M

                                                Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).

                                                  AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study

                                                  AstraZeneca PLC (AZN) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab).